What is the optimal treatment for a 60-year-old African American male with left kidney AL amyloidosis due to kappa light-chain restriction and an underlying plasma cell neoplasm?

Treatment for AL Amyloidosis with Kappa Light Chain Restriction and Plasma Cell Neoplasm

Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) is the standard of care first-line treatment for this 60-year-old patient with newly diagnosed AL amyloidosis affecting the kidney. 1

First-Line Treatment Recommendation

Initiate Dara-CyBorD immediately as the preferred regimen, which achieved unprecedented hematologic response rates of 78.5% very good partial response (VGPR) or better compared to 49.2% with CyBorD alone in the landmark ANDROMEDA trial. 1 This is the only FDA-approved regimen specifically for newly diagnosed AL amyloidosis. 1

Treatment Algorithm Based on Patient Characteristics

For this 60-year-old patient:

• Age 60 years makes him a borderline candidate for autologous stem cell transplantation (ASCT), which is typically reserved for patients <65 years with limited organ involvement. 1
• Assess cardiac involvement immediately by measuring NT-proBNP and troponin, performing echocardiography, and obtaining baseline MRI to determine Mayo stage and ASCT eligibility. 1
• If NT-proBNP >8,500 pg/mL or ejection fraction <40%, he is not an ASCT candidate and should receive Dara-CyBorD as definitive therapy. 1
• If Mayo stage 1-2 with preserved cardiac function (EF >40-45%), NYHA class <3, and eGFR >50 mL/min/1.74 m², consider 2-4 cycles of Dara-CyBorD as induction followed by high-dose melphalan with ASCT. 1, 2

Critical Diagnostic Confirmation Required

Before initiating any plasma cell-directed therapy, you must confirm this is truly AL amyloidosis and not LECT2 amyloidosis, which would require completely different management. 3

Mandatory Testing:

• Mass spectrometry of kidney biopsy tissue is the gold standard (88% sensitivity, 96% specificity) to definitively identify the amyloid protein as immunoglobulin light chain-derived. 3, 4
• Complete monoclonal protein screening including serum free light chain assay (sFLC) with kappa/lambda ratio, serum immunofixation electrophoresis (SIFE), and urine immunofixation electrophoresis (UIFE). 4
• Bone marrow biopsy to demonstrate clonal plasma cells producing kappa light chains. 4

Common pitfall: If immunofluorescence shows negative or equivocal staining for kappa and lambda light chains, this could be LECT2 amyloidosis rather than AL amyloidosis. 3 LECT2 amyloidosis requires no plasma cell-directed therapy and is managed with supportive care only. 3 Treating LECT2 amyloidosis with Dara-CyBorD would expose the patient to significant toxicity without benefit. 3

Dara-CyBorD Regimen Details

Dosing schedule:

• Daratumumab: 16 mg/kg IV weekly for cycles 1-2, every 2 weeks for cycles 3-6, then every 4 weeks thereafter 1
• Cyclophosphamide: 300 mg/m² orally weekly 1
• Bortezomib: 1.3 mg/m² subcutaneously twice weekly 1
• Dexamethasone: 20-40 mg weekly (reduce dose in elderly or those with cardiac involvement) 1

Monitoring for Cardiotoxicity

Daratumumab carries cardiac risks including heart failure (12%), cardiac arrhythmias (8%), and atrial fibrillation (6%). 1, 4

Mandatory monitoring:

• Measure NT-proBNP before each cycle to detect early cardiac decompensation. 1
• Obtain echocardiography at baseline, 3 months, and 6 months. 1
• Daily weights and careful fluid balance assessment. 1
• Close collaboration between hematology and cardiology is essential throughout treatment. 4

Response Assessment and Goals

Hematologic response criteria: 1

• Complete response (CR): Negative serum and urine immunofixation AND normal FLC ratio
• Very good partial response (VGPR): dFLC <40 mg/L
• Partial response (PR): dFLC decrease ≥50%

Target: Achieve at least VGPR within 3-6 months, as deeper hematologic responses correlate with better organ responses and survival. 1

Renal response criteria: 1

• At least 30% decrease in proteinuria or drop below 0.5 g/24 hours
• No >25% decrease in eGFR
• Organ response typically occurs 6-12 months after hematologic response. 1

Alternative Regimens if Dara-CyBorD Unavailable

If daratumumab is not accessible:

• CyBorD alone (cyclophosphamide, bortezomib, dexamethasone) is an acceptable alternative with 49.2% VGPR rate. 1
• Bortezomib-melphalan-dexamethasone (BMDex) is another option, particularly if t(11;14) cytogenetic abnormality is present. 1, 5

Relapsed/Refractory Treatment Options

If inadequate response to first-line therapy:

• Daratumumab monotherapy or daratumumab-based combinations remain the preferred second-line option with 63-100% overall response rate. 1
• Pomalidomide-dexamethasone for bortezomib-refractory disease, with 48-68% hematologic response rate and median time to response of 1-1.9 months. 1
• Lenalidomide-dexamethasone with caution due to risk of renal deterioration (66% incidence) and cardiac biomarker elevation. 1

Start lenalidomide at low dose (5-15 mg/day) in elderly patients or those with baseline cardiac involvement or elevated creatinine, with daily weights and frequent cardiac biomarker monitoring. 1

Supportive Care for Renal Involvement

Nephroprotective strategies: 3, 4

• ACE inhibitors or ARBs at lowest tolerated dose for blood pressure control
• Avoid NSAIDs and IV contrast to prevent further renal deterioration 4
• Monitor for progression with serial creatinine and 24-hour urine protein measurements 3
• Consider renal replacement therapy if eGFR continues declining despite treatment 3

Prognosis and Long-Term Monitoring

Cardiac involvement is the main driver of mortality in AL amyloidosis, not renal involvement. 4, 6 However, achieving deep hematologic responses (CR or VGPR) significantly improves both renal and cardiac outcomes. 1

Monitor for minimal residual disease (MRD): Patients achieving MRD-negativity by next-generation flow cytometry have higher rates of renal response (90% vs 62%, p=0.006) and lower risk of hematologic progression (0% vs 25% at 1 year, p=0.001). 1